Abstract:Human cerebrospinal fluid (CSF), produced by the choroid plexus and secreted into the brain ventricles and subarachnoid space, plays critical roles in intra-cerebral transport and the biophysical and immune protection of the central nervous system (CNS). CSF composition provides valuable insight into soluble pathogenic bio-markers that may be diagnostic for neurodegenerative disease. In these experiments we analyzed amyloid beta (Aβ) peptide and micro RNA (miRNA) abundance (i) in CSF, (ii) in short post-mortem interval brain tissue-derived extracellular fluid (ECF) and (iii) in brain tissue biopsy derived from Alzheimer's disease (AD) or age-matched control neocortex and/or hippocampal CA1. 3'-untranslated region (3'-UTR) sequence/vector analysis; Aβ42-peptide+TNFα-induced and/or hydrogen peroxide-induced stress; bioinformatics; CAPE, CAY10512, DNA array; DNA/RNA sequencing; human brain biopsy/postmortem tissue; human CSF;LED-Northern micro-dot blot analysis; micro-RNA array; protected anti-miRNAs; RT-PCR; statistical analysis, β-actin, TREM-2- and CFH-3'-UTR-luciferase-reporter transfection assay; UV/fluorescent microscopy; Western immuno-histochemistry. There was a trend for decreased-abundance of Aβ42 in the CSF and ECF in AD but it did not reach statistical significance (mean-age ∼72 yr; N=12; p∼0.06, ANOVA). The most abundant nucleic acids in AD-CSF and ECF were miRNAs and their speciation, abundance and inducibility were studied further. Comparison of miRNA signals between biopsy and post-mortem tissues (0.5–6 hrs) indicated a short half-life for many brain-enriched miRNAs. Fluorescent miRNA-array-based analysis indicated significant increases in miRNA-9, miRNA-34a, miRNA-125b, miRNA-146a and miRNA-155. Increases in miRNAs were confirmed independently using a highly-sensitive LED-Northern dot-blot assay. Primary human neuronal-glial cell co-cultures stressed with AD-derived ECF, TNFα or peroxide also displayed an up-regulation of these and other miRNAs. These effects were quenched using the anti-NF-КB agents caffeic acid-phenethyl-ester (CAPE) or 1-fluoro-2-[2-(4-methoxy-phenyl)-ethenyl]-benzene (CAY10512). The results indicate that miRNA-9, miRNA-34a, miRNA-125b, miRNA-146a and miRNA-155 are a family of inducible, NF-КB-sensitive pro-inflammatory miRNAs that are abundant in AD tissues and fluids. These AD-upregulated miRNAs further associate with deficits in the innate-immune response and the chronic and progressive spreading of inflammatory neurodegeneration. Enrichment of these miRNAs in circulating CSF and ECF suggest that they may be involved in the proliferation of miRNA-triggered pathogenic signaling throughout the AD brain and CNS.

miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease and other types of dementia – an exploratory study

Identification of Candidate Biomarkers of Alzheimer's Disease Via Multiplex Cerebrospinal Fluid and Serum Proteomics.

Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.

miRNAs in cerebrospinal fluid associated with Alzheimer's disease: A systematic review and pathway analysis using a data mining and machine learning approach

MicroRNA Complexity in Alzheimer's Disease Cerebrospinal Fluid, Extracellular Fluid and Brain Tissue Biopsy

Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease

Early Detection of Alzheimer’s Disease using microRNAs

Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment

Serum MicroRNA Profiles Serve As Novel Biomarkers for the Diagnosis of Alzheimer’s Disease

Genome-Wide Serum Microrna Expression Profiling Identifies Serum Biomarkers for Alzheimer'S Disease

Differential microRNA expression analyses across two brain regions in Alzheimer's disease

MicroRNA expression in extracellular vesicles as a novel blood‐based biomarker for Alzheimer's disease

Beyond CSF and Neuroimaging Assessment: Evaluating Plasma miR-145-5p as a Potential Biomarker for Mild Cognitive Impairment and Alzheimer’s Disease

Blood-based microRNAs as the potential biomarkers for Alzheimer's disease: evidence from a systematic review

Profiling of Serum Exosome MiRNA Reveals the Potential of a MiRNA Panel as Diagnostic Biomarker for Alzheimer’s Disease

Microrna (mirna) Speciation in Alzheimer's Disease (AD) Cerebrospinal Fluid (CSF) and Extracellular Fluid (ECF).

Quantification of microRNA-210 in the cerebrospinal fluid and serum: Implications for Alzheimer’s disease

Uncharacterized RNAs in Plasma of Alzheimer’s Patients Are Associated with Cognitive Impairment and Show a Potential Diagnostic Power

Peripheral Blood MicroRNA Expression Profiles in Alzheimer’s Disease: Screening, Validation, Association with Clinical Phenotype and Implications for Molecular Mechanism

MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy

Recognition of Alzheimer’s Disease Related miRNAs Based on Genome-Wide Association Study Data